Protein Characterization Through the Stages - Biomanufacturers should follow a risk-based approach to decide which methods to use to characterize their products. - BioPharm International

ADVERTISEMENT

Protein Characterization Through the Stages
Biomanufacturers should follow a risk-based approach to decide which methods to use to characterize their products.


BioPharm International Supplements


Current State of the Science


Table 1. Most commonly used characterization methods for biopharmaceutical products
Existing characterization methods are intended to provide a detailed, comprehensive analysis of protein size, charge, purity, activity, and structure (primary, secondary, and tertiary). These analyses also are used to examine impurity profiles, focusing particularly on aggregates, a key concern for regulatory agencies because of their potential immunogenicity.7 A broad range of analytical methods can be used to characterize proteins on the basis of identity, purity, yield, aggregation, specificity, and activity. These methods are used to assess comparability, form the basis for product release, determine product stability, and guide formulation development. Table 1 summarizes the most commonly used characterization methods for biopharmaceutical products.

Selecting the specific analytical methods to be used in characterizing a given biomolecule involves an assessment of the capabilities, advantages, and limitations of the available options. The sensitivity of the method in question is critical to identify minor contaminants or product variants that could potentially elicit significant immune responses in vivo. Reverse phase high performance liquid chromatography (RP-HPLC), mass spectrometry (MS), and dynamic light scattering (DLS) provide high sensitivity and are commonly used throughout the drug discovery-development-manufacturing chain. Size exclusion chromatography (SEC), analytical ultracentrifugation, and UV-Vis spectrophotometry are valued for their ability to accurately quantify specific analytes. Specificity is best determined with biological assays that mimic the desired in vivo molecular interactions in vitro, such as Western blots, enzyme assays, and cell-based assays.8 From both an operational and quality perspective, the best assays are robust, relatively insensitive to changes in sample matrix or product concentration, rapid, and easy to perform.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here